Table 1 Demographics and baseline characteristics

From: A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

 

Patients (N = 33)

Age, years, median (IQR)

50 (43–55)

ECOG performance status

  0

5 (15.2)

  1

28 (84.8)

No. of organs of metastases

  1

9 (27.3)

  2

11 (33.3)

  >2

13 (39.4)

Histological grade

  G2

10 (30.3)

  G3

4 (12.1)

  Unknown

5 (15.2)

  Undetermined

14 (42.4)

FIGO stage at initial diagnosisa

  I

12 (36.4)

  II

14 (42.4)

  III

5 (15.2)

  IV

1 (3.0)

  Unknown

1 (3.0)

PD-L1 expression

  Positive

10 (30.3)

  Negative

9 (27.3)

  Undetermined

14 (42.4)

No. of prior systemic therapy lines

  1

21 (63.6)b

  2

9 (27.3)

  ≥3

3 (9.1)

Prior systemic therapy

  Platinum

33 (100)

  Paclitaxel

32 (97.0)

  Bevacizumab

9 (27.3)

Prior radiation

32 (97.0)

Prior hysterectomy

22 (66.7)

Time from initial cancer diagnosis to study enrollment, months, median (IQR)

22.4 (12.8–38.5)

  1. Data are presented as n (%), unless otherwise specified. IQR interquartile range, ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics.
  2. aPatients were classified according to the 2009 FIGO staging for carcinoma of the cervix.
  3. bFive patients who received neoadjuvant or adjuvant therapy and developed disease relapse and progression within one year after surgery or six months after radiotherapy were included.
Back to article page